Month: March 2022

NFL Biosciences: 2021 full-year business and earnings update Phase II/III clinical trial rolled out for the drug candidate NFL-101 for smoking cessation: first patients recruited and recruitment capacity ramped up Organization further strengthened and active ingredient manufacturing partnership set up Intellectual property extended with an NFL Biosciences patent registered in the United States Co-development agreement signed for the drug candidate NFL-301 to reduce alcohol consumption NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, is reporting its 2021 full-year earnings, approved by the Board of Directors on March 24, 2022, while looking back on its progress following its admission to Euronext Growth Paris at the start of July...

WISeKey to Present at the Maxim Group 2022 Virtual Growth Conference on March 29th Geneva – March 28, 2022 – WISeKey International Holding Ltd. (“WISeKey,” SIX: WIHN / Nasdaq: WKEY), a leading global Semi-conductor, AI and IoT company, today announced that its CEO, Carlos Moreira is scheduled to participate in fireside chat at the Maxim Group Virtual Growth Conference on Tuesday, March 29, 2022 at 9:00am ET. Conference agenda and registration details can be found at https://m-vest.com/events/2022-virtual-growth-conference. Investors interested to schedule a one-on-one virtual meeting with management, can send an email to Investor Relations at lcati@equityny.com. Mr. Moreira’s discussion will focus on presenting the method used by WISeKey to secure the authenticity and provenance of assets through cutting-edge authentication processes...

Figure 1: Sissingué Mine Layout Figure 1: Sissingué Mine LayoutFigure 2: Fimbiasso Mine Layout Figure 2: Fimbiasso Mine LayoutFigure 3: Bagoé Mine Layout – Antoinette and Juliette deposits Figure 3: Bagoé Mine Layout – Antoinette and Juliette depositsFigure 4: Bagoé Mine Layout – Veronique deposit Figure 4: Bagoé Mine Layout – Veronique depositFigure 5: Sissingué – Scheduled monthly ex-pit material movement by deposit. Figure 5: Sissingué – Scheduled monthly ex-pit material movement by deposit.Figure 6: Sissingué – Annual Tonnes and Grade to SGM Mill Figure 6: Sissingué – Annual Tonnes and Grade to SGM MillFigure 1: SGM Mineralisation. Plan view of drillhole traces and Mineralised Domain. Figure 1: SGM Mineralisation. Plan view of drillhole traces and Mineralised Domain.Figure 7: Change in SGM Ore Reserves...

    Notice of annual general meeting in Terranet AB The shareholders of Terranet AB, reg. no. 556707-2128, (the “Company“) are hereby invited to the annual general meeting on Thursday 28 April 2022. Information with respect to the coronavirusThe Company is mindful of the health and well-being of its shareholders and employees. It is important for the Company to take a social responsibility and contribute to reduce the risk of transmission of the coronavirus (Covid-19). Consequently, the general meeting will be carried out through mandatory advance voting (postal voting) pursuant to temporary legislation. Thus, it will not be possible to attend in person or through proxy at the general meeting. Information on the decisions of the annual general meeting will be published as soon as the outcome of the postal voting is finally...

ATHENS, Greece, March 27, 2022 (GLOBE NEWSWIRE) — Imperial Petroleum Inc. is a ship-owning company providing petroleum product and crude oil seaborne transportation services announced today that it will release its fourth quarter and twelve months’ operating and financial results for the period ended December 31, 2021 before the market opens in New York on March 29, 2022. On March 29, 2022 at 11:00 am ET, the company’s management will host a conference call to discuss the results and the company’s operations and outlook. Conference Call details: Participants should dial into the call 10 minutes before the scheduled time using the following numbers: +18778709135 (US Toll Free Dial In) or 08002796619 (UK Toll Free Dial In).Access Code: 8576259                                                                    In case of any problems...

PASCAGOULA, Miss., March 26, 2022 (GLOBE NEWSWIRE) — HII (NYSE: HII) christened today pre-commissioning unit Jack H. Lucas (DDG 125) at the company’s Ingalls Shipbuilding division. Jack H. Lucas, a longtime resident of Hattiesburg, Mississippi, was the youngest Marine and youngest service member in World War II awarded the Medal of Honor. During a close firefight with Japanese soldiers, Lucas saved the lives of three Marines when he unhesitatingly placed himself on two grenades. “Jack H. Lucas made a selfless decision to choose others and country over self,” Ingalls Shipbuilding President Kari Wilkinson said. “Our Ingalls shipbuilders have a deep appreciation and respect for what sailors and Marines do on behalf of our nation. We are proud to support them and to provide them this remarkable ship, our first Flight III destroyer.” Chief...

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,527,121,390 €Registered office : 54, rue La Boétie – 75008 Paris – FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844Date   Total number of issued shares   Number of real voting rights(excluding treasury shares) Theoretical number of voting rights (including treasury shares)*February 28, 2022 1,263,652,025 1,405,189,490 1,420,184,443* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers. This...

PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) — Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB), at the 2022 American Academy of Dermatology Annual Meeting in Boston, Mass.  The data was presented by Peter Marinkovich, M.D., Director of the Blistering Disease Clinic at Stanford Health Care and Associate Professor of Dermatology at the Stanford University School of Medicine and primary investigator of the GEM-3 study, during the late-breaking research session. The full presentation is available in the Investors section of Krystal Biotech’s website. “We are very pleased...

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented a late-breaking oral abstract on data from a Phase 2 trial of EDP1815 in psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting, being held March 25-29 in Boston, Massachusetts. “We are proud to join the dermatology community at AAD to share the latest data from the clinical development of EDP1815 in psoriasis. The data being shared demonstrate the potential of Evelo’s SINTAX platform, and support progression towards registration trials for EDP1815,” said Douglas Maslin, M.Phil, M.B. B.Chir, Dermatology and Pharmacology Physician at Addenbrooke’s Hospital and...

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB Late-breaking oral presentation at the American Academy of Dermatology Annual meeting 2022 Body surface area percentage of partial thickness wounds reduced from 12.1% to 5.4% after at least 15 months of treatment with Oleogel-S10    No new safety signals observed DUBLIN, Ireland, and Boston MA, March 26, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announced new positive clinical data from EASE, the largest Phase 3 trial in Epidermolysis Bullosa (EB).  These data were presented during a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting 2022 held in Boston, MA.  Professor...